Drug Approval | December 04, 2025
FDA expands nod of Eli Lilly’s Jaypirca for earlier CLL/SLL treatment
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Jaypirca is making waves in the fight against B-cell malignancies
It is developing the drug candidate to potentially treat immunological diseases
Subscribe To Our Newsletter & Stay Updated
